Gain Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 10, 2026
GANX$1.08-0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · AccumulatedOtherComprehensive · · Accumulated · · · | |||||||||||||||||
| Three Months Ended September 30, 2026 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||
| Balance as of June 30, 2026 | | 43,340,501 | | $4,335 | | $121,924,254 | | $1,003,752 | | $(111,640,310) | | $11,292,031 | |||||
| Issuance of shares in at-the-market ("ATM") offering (Note 13) | | 978,260 | | | 98 | | | 1,777,991 | | | — | | | — | | | 1,778,089 |
| Stock-based compensation (Note 14) | | 5,373 | | 1 | | 372,048 | | — | | — | | 372,049 | |||||
| Changes in defined benefit pension plan obligation (Note 10) | | — | | — | | — | | (4,305) | | — | | (4,305) | |||||
| Foreign currency translation | | — | | — | | — | | (126,800) | | — | | (126,800) | |||||
| Net loss | | — | | | — | | | — | | | — | | | (3,160,408) | | | (3,160,408) |
| Balance as of September 30, 2026 | | 44,324,134 | | $4,434 | | $124,074,293 | | $872,647 | | $(114,800,718) | | $10,150,656 | |||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · AccumulatedOtherComprehensive · · Accumulated · · · | |||||||||||||||||
| Nine Months Ended September 30, 2026 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||
| Balance as of December 31, 2025 | | 42,073,807 | | $4,209 | | $119,139,677 | | $776,869 | | $(101,356,007) | | $18,564,748 | |||||
| Issuance of shares in ATM offering (Note 13) | | 1,941,962 | | | 194 | | | 3,597,037 | | | — | | | — | | 3,597,231 | |
| Exercise of warrants (Note 13) | | 229,710 | | | 23 | | | 2,039 | | | — | | | — | | 2,062 | |
| Stock-based compensation (Note 14) | | 78,655 | | | 8 | | | 1,335,540 | | | — | | | — | | 1,335,548 | |
| Changes in defined benefit pension plan obligation (Note 10) | | — | | | — | | | — | | | 56,280 | | | — | | | 56,280 |
| Foreign currency translation | | — | | | — | | | — | | | 39,498 | | | — | | | 39,498 |
| Net loss | | — | | | — | | | — | | | — | | | (13,444,711) | | | (13,444,711) |
| Balance as of September 30, 2026 | | 44,324,134 | | $4,434 | | $124,074,293 | | $872,647 | | $(114,800,718) | | $10,150,656 | |||||
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · Accumulated Other Comprehensive · · Accumulated · · · | |||||||||||||||||
| Three Months Ended September 30, 2025 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||
| Balance as of June 30, 2025 | | 30,771,321 | | $3,078 | | $94,642,942 | | $584,083 | | $(91,534,053) | | $3,696,050 | |||||
| Issuance of shares and warrants in public offering (Note 13) | | 5,176,886 | | | 518 | | | 7,015,558 | | | — | | | — | | | 7,016,076 |
| Exercise of warrants (Note 13) | | 25,300 | | | 3 | | | 41,742 | | | — | | | — | | | 41,745 |
| Stock-based compensation (Note 14) | | 2,883 | | — | | 460,793 | | — | | — | | 460,793 | |||||
| Changes in defined benefit pension plan obligation (Note 10) | | — | | — | | — | | 5,308 | | — | | 5,308 | |||||
| Foreign currency translation | | — | | — | | — | | (26,170) | | — | | (26,170) | |||||
| Net loss | | — | | | — | | | — | | | — | | | (5,284,373) | | | (5,284,373) |
| Balance as of September 30, 2025 | | 35,976,390 | | $3,599 | | $102,161,036 | | $563,221 | | $(96,818,426) | | $5,909,430 | |||||
| | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Common Stock · · AdditionalPaid-in · · Accumulated Other Comprehensive · · Accumulated · · · | |||||||||||||||||
| Nine Months Ended September 30, 2025 · · Shares · · Amounts · · Capital · · Income (Loss) · · Deficit · · Total | |||||||||||||||||
| Balance as of December 31, 2024 | | 27,132,588 | | $2,713 | | $88,779,318 | | $(247,549) | | $(81,194,908) | | $7,339,574 | |||||
| Issuance of shares in ATM offering (Note 13) | | 2,512,062 | | | 251 | | | 4,909,989 | | | — | | | — | | 4,910,240 | |
| Issuance of shares and warrants in public offering (Note 13) | | 5,176,886 | | | 518 | | | 7,015,558 | | | — | | | — | | | 7,016,076 |
| Exercise of warrants (Note 13) | | 1,056,902 | | | 108 | | | 41,742 | | | — | | | — | | 41,850 | |
| Stock-based compensation (Note 14) | | 97,952 | | | 9 | | | 1,414,429 | | | — | | | — | | 1,414,438 | |
| Changes in defined benefit pension plan obligation (Note 10) | | — | | | — | | | — | | | 16,068 | | | — | | | 16,068 |
| Foreign currency translation | | — | | | — | | | — | | | 794,702 | | | — | | | 794,702 |
| Net loss | | — | | | — | | | — | | | — | | | (15,623,518) | | | (15,623,518) |
| Balance as of September 30, 2025 | | 35,976,390 | | $3,599 | | $102,161,036 | | $563,221 | | $(96,818,426) | | $5,909,430 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.